ライフサイエンスコーパス: antiviral therapy

1 tion/disease after cessation of prophylactic antiviral therapy).

2 able serum HCV RNA 12 weeks after the end of antiviral therapy).

3 at the SLII domain is a potential target for antiviral therapy.

4 ubjects developed HBeAg seroconversion after antiviral therapy.

5 re longitudinally monitored before and after antiviral therapy.

6 ars) with chronic HBV infection treated with antiviral therapy.

7 ns is paramount in optimizing the success of antiviral therapy.

8 on, suggesting it may be a future target for antiviral therapy.

9 G should again only be used with concomitant antiviral therapy.

10 ppress viral replication and a potential pan-antiviral therapy.

11 mplications and could benefit from immediate antiviral therapy.

12 2 weeks of appropriately dosed and delivered antiviral therapy.

13 omen with chronic HBV infection treated with antiviral therapy.

14 f ZIKV and implicate AXL as a new target for antiviral therapy.

15 osed with chronic HBV infection who received antiviral therapy.

16 ore neurologic sequelae and may benefit from antiviral therapy.

17 G opsonizing activity and can be reversed by antiviral therapy.

18 ovides a novel target for the development of antiviral therapy.

19 s infection and may be effective targets for antiviral therapy.

20 nce, and those at risk of noncompliance with antiviral therapy.

21 r, there is currently no approved vaccine or antiviral therapy.

22 liver fibrosis as well as responsiveness to antiviral therapy.

23 eplication of HSV and a potential target for antiviral therapy.

24 rder to develop potential avenues for future antiviral therapy.

25 ed outcomes and would therefore benefit from antiviral therapy.

26 e pathway can provide a potential target for antiviral therapy.

27 s with stage 4 irrespective of the option of antiviral therapy.

28 med nuclear egress, an attractive target for antiviral therapy.

29 ction and uncover TJ proteins as targets for antiviral therapy.

30 ral life cycle and provides a new target for antiviral therapy.

31 RF57 provides further approaches to discover antiviral therapy.

32 ctive of origin, so that they can be offered antiviral therapy.

33 in intermediate and clinical outcomes after antiviral therapy.

34 to clear the virus (non-SVR; n = 183) after antiviral therapy.

35 n interface as a promising target for future antiviral therapy.

36 hepatitis B and major treatment endpoints of antiviral therapy.

37 V in patients with favorable genotypes under antiviral therapy.

38 ays 4 and 15, and week 8 after initiation of antiviral therapy.

39 seful tool in cancer, immune, antibiotic, or antiviral therapy.

40 d it has become a promising novel target for antiviral therapy.

41 ar RNAs, hence opening up unique avenues for antiviral therapy.

42 ith regular monitoring of HBV DNA and prompt antiviral therapy.

43 membranous web biogenesis-a new paradigm in antiviral therapy.

44 Six patients received prophylactic antiviral therapy.

45 aid in the targeting of these functions for antiviral therapy.

46 outcome of the infection and the response to antiviral therapy.

47 rong independent predictor of nonresponse to antiviral therapy.

48 lly has a benign course and may not prohibit antiviral therapy.

49 improved antagonists for use in combination antiviral therapy.

50 antibodies previously received IFN/ribavirin antiviral therapy.

51 lication and is thus an important target for antiviral therapy.

52 infection and as a potential drug target for antiviral therapy.

53 genomic RNA and is a primary drug target for antiviral therapy.

54 ed with unresponsiveness to interferon-based antiviral therapy.

55 istant viruses during core protein-targeting antiviral therapy.

56 42% had cirrhosis, and 54% had failed prior antiviral therapy.

57 d nuclear HBV DNA under conditions mimicking antiviral therapy.

58 fore, we propose it to be a novel target for antiviral therapy.

59 C virus (HCV) infection and their fate after antiviral therapy.

60 h reactivation can occur despite suppressive antiviral therapy.

61 lation did not change during the 12 weeks of antiviral therapy.

62 sessed and followed up through the course of antiviral therapy.

63 dividuals, and to enable linkage to care and antiviral therapy.

64 supports improved intermediate outcomes with antiviral therapy.

65 rvoir in infected individuals on suppressive antiviral therapy.

66 oncomitantly received nucleos(t)ide analogue antiviral therapy.

67 inically validated targets for direct-acting antiviral therapies.

68 n, and their ability to evolve resistance to antiviral therapies.

69 d targetable host factors for broad-spectrum antiviral therapies.

70 ng of the viral life cycle to develop better antiviral therapies.

71 ications for the development of vaccines and antiviral therapies.

72 not attain the new, expensive, direct-acting antiviral therapies.

73 ding survival, and reduce the need for toxic antiviral therapies.

74 HIV-1 capsid is a target of interest for new antiviral therapies.

75 tion, which increases cell susceptibility to antiviral therapies.

76 athogenesis and to the future development of antiviral therapies.

77 R12) during interferon-sparing direct-acting antiviral therapies.

78 paradigm shift and a new frontier for future antiviral therapies.

79 s, and yet there are no licensed vaccines or antiviral therapies.

80 vant to relapses observed with direct-acting antiviral therapies.

81 is critical for the development of targeted antiviral therapies.

82 the rt ORF, conferring resistance to current antiviral therapies.

83 a new quantitative method to evaluate future antiviral therapies.

84 infection and thus presents a new target for antiviral therapies.

85 ion, making this step a potential target for antiviral therapies.

86 ging field that is destined to suggest novel antiviral therapies.

87 ng drug-resistant variants emerging with new antiviral therapies.

88 that may ultimately enable escape-resistant antiviral therapies.

89 the chronopharmacology of antibacterial and antiviral therapies.

90 has hampered the development of appropriate antiviral therapies.

91 lication will guide the development of novel antiviral therapies.

92 KO hamster model for evaluation of promising antiviral therapies.

93 currently no licensed filovirus vaccines or antiviral therapies.

94 ion reveals potential avenues for developing antiviral therapies.

95 os(t)ide analogues are 2 classes of approved antiviral therapies.

96 ith neither effective vaccines, nor specific antiviral therapies [1,2].

97 entage of patients who required CMV directed antiviral therapy (17% vs 36%, P = .01) and in the total

98 Despite antiviral therapy, 3 (75%) patients died.

99 n specialty care were more likely to receive antiviral therapy (50% versus 24% for specialty care ver

100 ough it was lower than those recommended for antiviral therapy (78.2%).

101 Even after years of fully effective antiviral therapy, a persistent reservoir of virus-infec

102 However, we have no antiviral therapies against alphaviral disease, and curr

103 e critical for the future design of curative antiviral therapies against chronic hepatitis B.

104 There are no vaccines or antiviral therapies against HAstV disease.

105 IE could facilitate the development of novel antiviral therapies against viral diseases.

106 ntially expand the repertoire of targets for antiviral therapy against negative-strand RNA viruses.

107 Oral antiviral therapy alone without hepatitis B immune globu

108 ently limited data regarding the use of oral antiviral therapy alone without hepatitis B immune globu

109 that can be reduced, but not solved, through antiviral therapy alone.

110 of increased resource utilization for novel antiviral therapies and liver transplantation continues

111 ons for the combined use of CoRAs and FIs in antiviral therapies and point to a multifaceted role for

112 In the absence of effective antiviral therapies and vaccines, these viruses pose ser

113 ical responses, animal models, and potential antiviral therapies and vaccines.

114 We measured hsa-miRNAs before and after antiviral therapy and correlated hsa-miRNA expression le

115 improved virological response (VR) rates to antiviral therapy and decreased progression of liver fib

116 e stability of HBV cccDNA in the presence of antiviral therapy and during cell division induced by im

117 researchers understand the controversies in antiviral therapy and immunogenetics of this cancer and

118 hort of veterans with hepatitis B infection; antiviral therapy and liver imaging were independently a

119 clinical and clinical studies of combination antiviral therapy and of combined antiviral-immunomodula

120 detected at early stages, can be cured with antiviral therapy and reduced administration of immunosu

121 The unmet need for antiviral therapy and vaccination against RSV in adults

122 ensive supportive treatment and experimental antiviral therapies, and had been discharged with undete

123 on in patient-derived hepatocytes, action of antiviral therapies, and the biology of HCV infection.

124 hat can be targeted for viral attenuation or antiviral therapies, and we suggest that the RdRp may no

125 teractions, help to identify new targets for antiviral therapy, and allow for the development of new

126 nd resistance testing was performed prior to antiviral therapy, and in patients with delayed treatmen

127 , it should be administered with concomitant antiviral therapy, and that evidence concerning preempti

128 ding, multi-drug resistance during prolonged antiviral therapy, and the potential high risk of pulmon

129 An SVR after antiviral therapy appears associated with improved clini

130 t prophylaxis with CMVIG in combination with antiviral therapy appears effective in D+/R- heart trans

131 Since there is currently no vaccine or antiviral therapy approved for humans, there is an urgen

132 l threat to public health and no vaccines or antiviral therapies are approved for dengue fever.

133 n in affected areas, no licensed vaccines or antiviral therapies are available.

134 Though highly effective direct-acting antiviral therapies are costly, the price of a cure is a

135 Since specific antiviral therapies are not available for the treatment

136 buted human pathogens for which vaccines and antiviral therapies are urgently needed.

137 Nonetheless, many novel approaches to antiviral therapy are available, including candidate thi

138 lic health threat worldwide, and options for antiviral therapy are limited by the emergence of drug-r

139 Studies on antiviral therapy are undergoing to elucidate the optima

140 Clinical trials of antiviral therapy are warranted for treatment and preven

141 Direct-acting antivirals therapies are now emerging, providing the opp

142 the absence of licensed vaccines or specific antiviral therapies, are recognized to pose significant

143 cial for maximizing the benefit of available antiviral therapy, as treatment efficacy rapidly decreas

144 eduction in immunosuppression and preemptive antiviral therapy, at the discretion of the attending te

145 manized mice and patients, and direct-acting antiviral therapy attenuated M2 macrophage activation an

146 ter informed consent, all patients underwent antiviral therapy (AVT) with sofosbuvir/ledipasvir and c

147 virus and may lead to the discovery of novel antiviral therapies based on metabolic inhibitors.

148 S2 fibrosis patients with hepatitis C virus antiviral therapy before CRT.

149 Interferon-alpha therapy may be an effective antiviral therapy beneficial in chronic HBV-infected chi

150 such patients might not require pre-emptive antiviral therapy, but should be followed up on a monthl

151 Antibodies have a long history in antiviral therapy, but until recently, they have not bee

152 driven assessment, triage, and management of antiviral therapy by specifically trained nurses, with s

153 Although standard antiviral therapies can suppress active viral replicatio

154 However, CMV antiviral therapy can be complicated by drug resistance

155 spective cohort, we report on the success of antiviral therapy combined with a short course (in hospi

156 CTs with posttreatment follow-up <12 months, antiviral therapy compared to placebo improved alanine a

157 n a patient reduces the clinical efficacy of antiviral therapy, complicates therapeutic and clinical

158 ence of early CMV reactivation (and BM-toxic antiviral therapy), cotransplantation of host Treg cell

159 allow a review of the competing theories of antiviral therapy development in the field of HCV virolo

160 ove that provided by current ART or proposed antiviral therapies directed at limiting Nef, Vpr, or Vp

161 he efficacy and maternal and fetal safety of antiviral therapy during pregnancy.

162 ed susceptibility will aid in developing new antiviral therapies for asthmatic patients.

163 currently no effective vaccines or specific antiviral therapies for DENV, we investigated the impact

164 ola virus and report the use of experimental antiviral therapies for Ebola PEP in people.

165 Thus, BocaSR may be a target for antiviral therapies for HBoV and may also have utility i

166 With the advent of highly efficient antiviral therapies for hepatitis C virus (HCV) infectio

167 re are currently no FDA-licensed vaccines or antiviral therapies for VEEV.

168 Administration of antiviral therapy for 48 weeks reversed aberrant IgG-Fc

169 of cCMV screening were assumed to come from antiviral therapy for affected newborns to reduce hearin

170 Prolonged antiviral therapy for both VZV and HIV type 1 was associ

171 Antiviral therapy for cytomegalovirus (CMV) plays an imp

172 systematically assessed before starting the antiviral therapy for early detection and the improvemen

173 Clinicians should start antiviral therapy for HBsAg-positive/anti-HBc-positive p

174 ity-based screening and early treatment with antiviral therapy for HBV in The Gambia.

175 Sofosbuvir-based antiviral therapy for HCV recurrence after liver transpl

176 also been included in interferon-free direct antiviral therapy for HCV, modulate host immune response

177 of 233 HIV/HCV-coinfected patients received antiviral therapy for HCV, of whom 106 (45%) achieved su

178 Little is known about the benefit of antiviral therapy for hepatitis B e antigen (HBeAg)-posi

179 In recent years, short-term antiviral therapy for pregnant women in the third trimes

180 e supporting the use of intravenous and oral antiviral therapy for the treatment of ARN.

181 There is no specific antiviral therapy for WNV, but studies of antivirals spe

182 rise of resistance mutations against current antiviral therapies has increased the need for the devel

183 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of sho

184 Currently available direct-acting antiviral therapies have reduced efficacy in patients wi

185 emia to below the limit of detection without antiviral therapy have been termed elite controllers (EC

186 Although recent advances in antiviral therapy have led to significant improvements i

187 Antiviral therapy (hazard ratio = 0.85, 95% confidence i

188 e been suggested to be potential targets for antiviral therapies, identification of these molecules i

189 rn sericulture but also shed light on future antiviral therapy.IMPORTANCE Pathogen genome targeting h

190 es and may provide an alternative target for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV

191 nic HBV infection, antivirals compared to no antiviral therapy improve HBV DNA suppression and freque

192 s with posttreatment follow-up >/=12 months, antiviral therapy improved cumulative HBeAg clearance/lo

193 Antiviral therapy improves HBV suppression and reduces M

194 itis B immune globulin and vaccination, oral antiviral therapies in highly viremic mothers can furthe

195 recovered from hepatitis B will benefit from antiviral therapy in certain circumstances because of th

196 d/or HBsAg are critical endpoints for future antiviral therapy in chronic HBV.

197 ensitivity, and changes in viral load during antiviral therapy in finger-stick DBS were compared to t

198 r questions about stopping versus continuing antiviral therapy in hepatitis B e antigen-negative pati

199 stions about discontinuing versus continuing antiviral therapy in hepatitis B e antigen-positive pati

200 ating HSV encephalitis is clear, the role of antiviral therapy in HSV meningitis remains controversia

201 Prophylactic antiviral therapy in immunocompetent cytomegalovirus ser

202 ic outcomes were significantly improved with antiviral therapy in immunocompromised patients with her

203 s B e antigen (HBeAg) status and response to antiviral therapy in patients with chronic hepatitis B (

204 lity evidence supported the effectiveness of antiviral therapy in patients with immune active chronic

205 size evidence regarding the effectiveness of antiviral therapy in the management of chronic HBV infec

206 safe use of in vitro expanded CMV-CTLs as an antiviral therapy in transplant patients with refractory

207 utcomes and to evaluate the effectiveness of antiviral therapy in treating SFTS virus (SFTSV)-infecte

208 Current antiviral therapies include oseltamivir, a neuraminidase

209 nts of rational strategies for the design of antiviral therapies, including monoclonal antibodies (mA

210 atment of addiction, support services during antiviral therapy increased treatment completion (P < .0

211 and safety of sofosbuvir-based direct-acting antiviral therapy, individually tailored according to th

212 Spontaneous, but not antiviral therapy-induced, viral clearance was associate

213 Current antiviral therapy inhibits cytoplasmic HBV genomic repli

214 revalence of recommended laboratory testing, antiviral therapy initiation, and liver imaging among a

215 stodial settings worldwide, yet provision of antiviral therapies is uncommon.

216 Short-term pretransplant antiviral therapy is a feasible strategy in preventing H

217 Antiviral therapy is a first line of defence against new

218 However, no specific antiviral therapy is available at present.

219 Initial oral or intravenous antiviral therapy is effective in treating ARN.

220 Effective antiviral therapy is essential for achieving sustained v

221 impact the probability of cure provided that antiviral therapy is given concurrently during eradicati

222 short course of HBIG combined with long-term antiviral therapy is highly effective in preventing HBV

223 An obvious strategy to optimise antiviral therapy is to combine drugs with different mod

224 ir accumulation over time in patients before antiviral therapy is underexplored, in large part becaus

225 one of the biggest challenges for successful antiviral therapy, it has also inspired mathematical mod

226 of magnitude among individual cells and that antiviral therapy leads to a reduction in nuclear DNA in

227 patocytes, even in the presence of available antiviral therapies, lies in the accumulation of covalen

228 ish patients who would benefit the most from antiviral therapy, mainly with aerosolized ribavirin.

229 Antiviral therapy may be considered in pregnant women wi

230 e basis of 11 primarily fair-quality trials, antiviral therapy may be more effective than placebo for

231 ation of intravitreal foscarnet and systemic antiviral therapy may have greater therapeutic efficacy

232 needs to be improved; our data suggest that antiviral therapy may lead to a reduced stroke risk foll

233 Antiviral therapy might provide protective benefits on a

234 ere randomly assigned to receive combination antiviral therapy (n=316) or monotherapy (n=317).

235 Thus, despite successful antiviral therapy, numerous studies suggest a role of ch

236 This unique case explores the response to antiviral therapies of a CHB with concurrent HBsAg and H

237 Combination direct-acting antiviral therapy of 8-24 weeks is highly effective for

238 IFNalpha-based antiviral therapy of hepatitis delta was independently a

239 ect of sustained virologic response (SVR) to antiviral therapy on the risk of developing hepatocellul

240 There are no effective antiviral therapies or licensed vaccines for this virus,

241 Additionally, no specific antiviral therapies or vaccines currently exist for huma

242 Currently, no specific antiviral therapies or vaccines exist for use in humans

243 Without effective antiviral therapies or vaccines, these viruses pose seri

244 e subject suggests either unrecognized prior antiviral therapy or infection by an inoculum from a tre

245 At present, no effective antiviral therapy or licensed vaccine exists, and treatm

246 patients in C-SURFER who received immediate antiviral therapy or who received placebo before therapy

247 o the introduction of varicella vaccination, antiviral therapy, or change in the prevalence of immuno

248 d laboratory evaluations for eligibility for antiviral therapy over 24 months.

249 After antiviral therapy, patients had increased numbers of T-r

250 r study including 168 HCV patients receiving antiviral therapy (peginterferon alpha-2b and ribavirin)

251 Antiviral therapy reduced MTCT, as defined by infant hep

252 The patient received different antiviral therapy regimens (pegylated interferon alpha 2

253 V) is very large, yet the uptake of curative antiviral therapies remains very low, reflecting the mar

254 Current antiviral therapy remains effective for the majority of

255 stant CMV infection or who are intolerant to antiviral therapy require alternative strategies.

256 been linked with a differential response to antiviral therapy, risk of steatosis and fibrosis, as we

257 The newly approved antiviral therapies sofosbuvir and simeprevir, with sign

258 virus pathogenesis, virus transmission, and antiviral therapy studies.

259 e advent of safe and effective direct-acting antiviral therapy, such that most patients can be cured

260 h detectable viremia who received preemptive antiviral therapy, suggesting that the adaptive NK cell

261 er understanding for the design of candidate antiviral therapies targeting drug-abusing individuals.

262 s also the case for ribosomal frameshifting, antiviral therapies targeting readthrough with inhibitor

263 ective hepatitis C virus (HCV) direct-acting antiviral therapies that do not require modification of

264 versal hepatitis B vaccination and effective antiviral therapy, the estimated overall seroprevalence

265 ls are focused on IFN-lambda1 as a potential antiviral therapy, the finding that IFN-lambda3 invariab

266 In the absence of antiviral therapy, this process results in clinical dise

267 liminate HIV-1 in individuals on suppressive antiviral therapy, those approaches will need to elimina

268 ave potential implications for the timing of antiviral therapy to achieve better virus control.

269 ortunately, there are currently no effective antiviral therapy to contain HCoV-NL63 infection.

270 Pretransplant antiviral therapy to eradicate HCV reduces recurrence, b

271 Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damag

272 ce antigen-positive should start appropriate antiviral therapy to prevent reactivation.

273 and identify the patients who require timely antiviral therapy to prevent the development of detrimen

274 to determine the impact of adding statins to antiviral therapy upon sustained virological response (S

275 Antiviral therapy using newer nucleos(t)ide analogues wi

276 ntigen (HBsAg) rapid test and subsequent HBV antiviral therapy versus current practice, in which ther

277 HBV infection had to be receiving effective antiviral therapy (viral load <100 IU/mL); antiviral the

278 The first episode of CMV viremia requiring antiviral therapy was assessed in 282 patients (147 CMV

279 Antiviral therapy was associated with a higher risk for

280 Antiviral therapy was associated with improvement in sur

281 Prolonged antiviral therapy was given to 226 (80.1%) of 282 patien

282 e basis of 22 primarily fair-quality trials, antiviral therapy was more effective than placebo for va

283 risk for progression to LRTI and death when antiviral therapy was not given (6.5 [95% confidence int

284 e antiviral therapy (viral load <100 IU/mL); antiviral therapy was not required for patients with HCV

285 At multivariate analysis, nonresponse to antiviral therapy was predicted by carriage of interleuk

286 eficits might be reversible after successful antiviral therapy, we analyzed the long-term course of n

287 Here, to investigate a new mechanism for antiviral therapy, we tested the effect of various autop

288 erring immunological escape or resistance to antiviral therapies were found neither in HBsAg nor in H

289 les were included, clinical outcome data for antiviral therapies were limited, and several studies we

290 Adults with chronic HBV not receiving antiviral therapy were enrolled from 21 centers in North

291 sis, HCV-specific graft loss and response of antiviral therapy were examined.

292 odes (18 = brincidofovir; 23 = cidofovir) of antiviral therapy were observed in 27 patients.

293 ho were followed for at least 1 year without antiviral therapy, were enrolled.

294 imicking chronic infections with and without antiviral therapy, which prevents de novo viral replicat

295 omes might be gained from the combination of antiviral therapy with drugs that modulate the immune re

296 HCV-seropositive patients who had undergone antiviral therapy with ribavirin and pegylated IFN.

297 ve observational cohort study, direct-acting antiviral therapy with SOF/ledipasvir, ombitasvir/parita

298 onic HCV infection before, during, and after antiviral therapy with sofosbuvir and velpatasvir, we fo

299 A total of 37% received antiviral therapy, with higher rates of sustained virolo

300 als that could lead to intrinsic combination-antiviral therapies within a single molecule-evolutionar